Wang v. Zymergen Inc.

District Court, N.D. California·Decided December 16, 2024·No. 5:21-cv-06028·Unknown

Opinion

BIAO WANG, Case No. 21-cv-06028-PCP

Lead Plaintiff, ORDER DENYING MOTION TO v. CERTIFY ORDER FOR INTERLOCUTORY APPEAL ZYMERGEN INC., et al., Re: Dkt. No. 399 Defendants.

Lead plaintiff Biao Wang represents a putative class of people alleging securities fraud arising from defendant Zymergen, Inc.’s initial public offering in 2021. Two classes of defendants—certain management companies and their funds—moved to dismiss Mr. Wang’s second amended complaint as barred by the relevant statute of limitations. The Court denied those motions. The management companies and funds now ask the Court to certify the order denying their motion to dismiss for interlocutory appeal under 28 U.S.C. § 1292(b). For the following reasons, the Court denies the defendants’ motions. The Court accepts the following allegations from the complaint in resolving these motions. This case arises from materials manufacturing startup Zymergen’s IPO in April 2021. Zymergen went public at $31 per share, touting its “biofacturing” process that would allow Zymergen to make products “faster, cheaper and more sustainably than traditional chemistry.” It sold around 18.5 million shares of common stock at $31 per share in the first public offering, yielding proceeds of nearly $530 million. Its registration statement discussed various products in Zymergen’s development pipeline, estimating a total market opportunity of $1.2 trillion across in late 2021. Mr. Wang alleges that these and other statements were either untrue statements of material fact or that they omitted material facts about Zymergen’s business projections. Less than four months after its IPO, Zymergen revealed “issues with its commercial product pipeline” that would impact its “delivery timeline and revenue projections.” The company said it no longer expected revenue in 2021 and expected immaterial revenue in 2022. It also announced that the CEO was stepping down. Zymergen’s stock price fell from $26.58 per share to $8.25 per share the following day. Over the next few months Zymergen announced layoffs of 220 employees. Cofounder Jed Dean stepped down. News reports compared Zymergen to Theranos and addressed how the company “imploded.” In November 2021, the company announced that it was discontinuing Hyaline and that it was under investigation by the SEC. In October 2022, more than a year after the IPO, Zymergen completed an all-stock merger to become a subsidiary of Ginkgo Bioworks Holdings, Inc. Zymergen shareholders received Ginkgo shares at a rate that valued Zymergen at less than one tenth of its IPO valuation. A year later, in October 2023, Zymergen filed a Chapter 11 bankruptcy petition. * * * Zymergen had three early investors: DCVC, True Ventures, and SoftBank. DCVC was Zymergen’s initial seed investor.1 It invested around $44 million before Zymergen’s IPO and received the right to appoint one of Zymergen’s board members as a condition of investment. True Ventures was another seed investor.2 It invested around $75 million before the IPO and also received the right to appoint a board member. SoftBank was Zymergen’s largest pre-IPO investor.3 It invested around $404 million and received the right to appoint a board member and to have that board member serve on every board committee. 1 Except where noted, this order refers collectively to the management companiesand the individual funds they managed as “investor defendants.” Defendant DCVC Management Co, LLC manages the defendant funds Data Collective II, L.P. and DCVC Opportunity Fund, L.P. 2 Defendant True Venture Management, L.L.C. manages the defendant funds True Ventures IV, L.P.; True Ventures Select I, L.P.; True Ventures Select II, L.P.; True Ventures Select III, L.P.; and True Venture Select IV, L.P. At the time of Zymergen’s public offering, these three investors were Zymergen’s three largest shareholders, and the only investors entitled to appoint board members. SoftBank owned around a third of Zymergen’s shares, while DCVC and True Ventures each owned just under 10%. Together, the three investors owned more than half of Zymergen’s outstanding shares before the public offering, including nearly 60% of its preferred shares. Zymergen’s governance documents required that the company obtain approval from at least two of these three investors for most business matters, including adopting any budget or business plan, hiring executives, granting stock or options, entering or exiting a line of business, or incurring debt. Zymergen could not amend its governing documents or issue common stock without all three investors’ consent. The three investors also entered an agreement to vote their shares together on certain issues, including each firm’s board nominee. The investors required that Zymergen indemnify not only their board appointees but also the firms and associated individuals from certain securities claims arising from their appointees’ board service. The complaint asserts that serving on Zymergen’s board, controlling Zymergen, and signing its registration statement fell within the scope of the respective agency relationships between the VC firms and their board appointees. Each of the appointed board members served on the boards of multiple companies in which his respective VC firm had invested. During the lead up to Zymergen’s public offering, the three VC firm board appointees were the three sole members of the Zymergen board’s audit committee, which controlled Zymergen’s financial statements and its internal audit function. * * * Mr. Wang filed his initial complaint on August 4, 2021. The complaint named as defendants Zymergen, Josh Hoffman (Zymergen’s CEO), Enakshi Singh (Zymergen’s CFO), the other members of Zymergen’s board, and the underwriters of the IPO. On February 24, 2022, Mr. Wang filed his first amended complaint. Dkt. No. 78. This complaint added the individual SoftBank, True Ventures, and DCVC funds (but not the management companies) as defendants. It included a claim under Section 11 of the Securities Act against Zymergen, the individual board defendants and the three investors. Three motions to dismiss followed: one by Zymergen, the individual defendants, and the True Ventures funds (also joined by the underwriters); one by the DCVC funds; and one by the SoftBank funds. On November 29, 2022, the Court denied the motions to dismiss as to the Section 11 claim and granted them as to the Section 15 claim. Dkt. No. 162, 2022 WL 17259057 (Chhabria, J.). The order stated that the dismissal of the Section 15 claim was “with leave to amend” and that an “amended complaint is due within 28 days of this order.” But the order also noted that “if the plaintiffs wish to proceed on this complaint, they can always seek leave to amend at a later stage if discovery reveals additional information relevant to the dismissed claims.” Mr. Wang did not file an amended complaint within 28 days. After this case was assigned to a new district judge on December 21, 2023, Mr. Wang moved for leave to file a second amended complaint reasserting the Section 15 claims against the individual defendants and the SoftBank, DCVC, and True Ventures funds. He also sought to add the three separate management companies as defendants to the Section 15 claim. The Court granted Mr. Wang’s motion. The SoftBank, DCVC, and True Ventures defendants thereafter moved to dismiss the second amended complaint. As relevant here, the defendants asserted a statute of limitations defense, arguing that Mr. Wang’s claims against them were time barred. The Court rejected the statute of limitations defense as to both the funds and the management companies. First, the Court held that the claims against the fund defendants related back to the filing of the first amended complaint. Although the Court had previously dismissed the claims against the fund defendants, that dismissal was without prejudice

Free access — add to your briefcase to read the full text and ask questions with AI

Wang v. Zymergen Inc., (N.D. Cal. 2024).

Wang v. Zymergen Inc. (Wang v. Zymergen Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related